Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia

Sponsor
Yonsei University (Other)
Overall Status
Completed
CT.gov ID
NCT01506622
Collaborator
(none)
222
1
3
11
20.2

Study Details

Study Description

Brief Summary

The occurrence of emergence agitation (EA) in pediatric patients who have received sevoflurane anesthesia is a common postoperative problem. The prevalence of EA varies between 10% to 80% depending on the scoring system for evaluation and the anesthetic technique used.

Many authors reported various strategies such as use of sedative premedication, change of maintenance technique of anesthesia, or pharmacological agents administered at the end of anesthesia to reduce the incidence and severity of EA, and to allow a smooth emergence from sevoflurane anesthesia. Among these strategies, the use of pharmacological agents at the end of anesthesia is not affected by anesthetic duration, and may not prolong recovery duration of anesthesia excessively when these agents are administered as subhypnotic or small dose. The typical agents that can be administered in this way are propofol and fentanyl.

Previous studies demonstrated that the use of either propofol or fentanyl at the end of anesthesia could reduce the incidence of EA.

The purpose of this study is to compare the preventive effect on EA and the characteristics of anesthesia recovery between propofol and fentanyl administered at the end of sevoflurane anesthesia.

Condition or Disease Intervention/Treatment Phase
  • Drug: Administration of propofol
  • Drug: Administration of fentanyl
  • Drug: Administration of saline
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
222 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Care Provider, Investigator)
Study Start Date :
Jan 1, 2011
Actual Primary Completion Date :
Dec 1, 2011
Actual Study Completion Date :
Dec 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Propofol group

intravenous administration of propofol 1 mg/kg at the end of anesthesia

Drug: Administration of propofol
Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.

Active Comparator: Fentanyl group

intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia

Drug: Administration of fentanyl
Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.

Active Comparator: Control group

intravenous administration of saline at the end of anesthesia

Drug: Administration of saline
Saline will be administered to control group at the end of anesthesia.

Outcome Measures

Primary Outcome Measures

  1. The incidence of emergence agitation [Participants will be followed for the duration of postanesthesia care unit (PACU) stay, an expected average of one hour.]

    The investigator will evaluate the incidence and extent of emergence agitation of participants, according to Aono's scale, the 5-step Emergence Agitation (EA) scale. Also, the Pediatric Anesthesia Emergence Delirium (PAED) scale will be used to assess emergence agitation. Aono's scale scores ≥3, 5-step (EA) scale ≥4 or PAED scale scores ≥10 will be considered as presence of emergence agitation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Months to 72 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists I or II,

  • 18-72 months of age,

  • scheduled for ambulatory inguinal hernia repair undergoing general sevoflurane anesthesia

Exclusion Criteria:
  • developmental delay

  • psychological and neurologic disorder

  • sedatives medication

  • an abnormal airway

  • reactive airway disease

  • extreme agitation and uncooperation

  • previous history of anesthesia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yonsei University Seoul Korea, Republic of

Sponsors and Collaborators

  • Yonsei University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yonsei University
ClinicalTrials.gov Identifier:
NCT01506622
Other Study ID Numbers:
  • 4-2010-0536
First Posted:
Jan 10, 2012
Last Update Posted:
Jul 16, 2015
Last Verified:
Jul 1, 2015
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2015